Risk and management of pre-diabetes.


Journal

European journal of preventive cardiology
ISSN: 2047-4881
Titre abrégé: Eur J Prev Cardiol
Pays: England
ID NLM: 101564430

Informations de publication

Date de publication:
Dec 2019
Historique:
entrez: 27 11 2019
pubmed: 27 11 2019
medline: 6 10 2020
Statut: ppublish

Résumé

Type 2 diabetes mellitus (T2DM) is associated with a two- to four-fold increased risk of developing cardiovascular disease (CVD) and microvascular complications, which may already be present before diagnosis. It is, therefore, important to detect people with an increased risk of T2DM at an early stage. In order to identify individuals with so-called 'pre-diabetes', comprising impaired fasting glucose (IFG) and impaired glucose tolerance (IGT), current guidelines have developed definitions based on fasting plasma glucose, two-hour glucose concentrations and haemoglobin A1c. Subjects with pre-diabetes are at an increased risk of developing T2DM and CVD. This elevated risk seems similar according to the different criteria used to define pre-diabetes. The risk of progression to T2DM or CVD does, however, depend on other risk factors such as sex, body mass index and ethnicity. Based on the risk factors to develop T2DM, many risk assessment models have been developed to identify those at highest risk. These models perform well to identify those at risk and could be used to initiate preventive interventions. Many studies have shown that lifestyle modification and metformin are effective in preventing the development of T2DM, although lifestyle modification seems to have a more sustainable effect. In addition, lifestyle modification seems more effective in those with IGT than those with IFG. In this review, we will describe the different definitions used to define pre-diabetes, progression from pre-diabetes to T2DM or other vascular complications, risk factors associated with progressions and the management of progression to T2DM, ending with clinical recommendations.

Identifiants

pubmed: 31766914
doi: 10.1177/2047487319880041
doi:

Substances chimiques

Glycated Hemoglobin A 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

47-54

Auteurs

Jwj Beulens (J)

Department of Epidemiology and Biostatistics, Amsterdam UMC - Location VU, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.
Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.

F Rutters (F)

Department of Epidemiology and Biostatistics, Amsterdam UMC - Location VU, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.

L Rydén (L)

Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.

O Schnell (O)

Forschergruppe Diabetes eV, Muenchen-Neuherberg, Germany.

L Mellbin (L)

Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.

H E Hart (HE)

Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
Leidsche Rijn Julius Health Centers, Utrecht, The Netherlands.

R C Vos (RC)

Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
Leiden University Medical Center, Department of Public Health and Primary Care, LUMC-Campus The Hague, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH